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Abstract
AIM: To investigate the relationship between ferritin 
and steatosis in patients with chronically abnormal 
liver function tests (LFTs) and high ferritin level. 
METHODS: One hundred and twenty-four consecutive 
patients with hyperferritinemia (male > 300 ng/mL, 
female > 200 ng/mL) were evaluated; clinical, biochemical 
and serological data, iron status parameters, HFE gene 
mutations and homeostasis model assessment score 
were obtained. Steatosis was graded by ultrasound as 
absent or present. Histology was available in 53 patients 
only.
RESULTS: Mean level of ferritin was 881 ± 77 ng/mL 
in men and 549 ± 82 ng/mL in women. The diagnosis 
was chronic hepatitis C in 53 (42.7%), non-alcoholic 
fatty liver disease/non-alcoholic steatohepatitis in 57 
(45.9%), and cryptogenic liver damage in 14 (11.3%). 
None was diagnosed as hereditary hemochromatosis 
(HH). Hepatic siderosis on liver biopsy was present in 
17 of 54 (32%) patients; grade 1 in eight and grade 2 
in nine. Overall, 92 patients (74.2%) had steatosis. By 
logistic regression, ferritin and g-glutamyltransferase 
were independent predictors of steatosis. Ferritin 
levels were significantly related to low platelet count, 
steatosis and hepatitis C virus infection. 
CONCLUSION: In a non-obese cohort of non-alcoholic 
patients with chronically abnormal LFTs without HH, 
high serum ferritin level is a risk factor for steatosis.
© 2009 The WJG Press and Baishideng. All rights reserved.
Key words: Steatosis; Serum ferritin; Chronic liver 
disease; Hepatitis C; g-glutamyltransferase
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Licata A, Nebbia ME, Cabibbo G, Lo Iacono G, Barbaria F, 
Brucato V, Alessi N, Porrovecchio S, Di Marco V, Craxì A, 
Cammà C. Hyperferritinemia is a risk factor for steatosis in 
chronic liver disease. World J Gastroenterol 2009; 15(17): 
2132-2138  Available from: URL: http://www.wjgnet.
com/1007-9327/15/2132.asp  DOI: http://dx.doi.org/10.3748/
wjg.15.2132
INTRODUCTION
There may be high serum ferritin levels in systemic 
inf lammatory conditions and in renal , l iver and 
neoplastic diseases[1,2]. Among patients with chronic liver 
disease, high serum ferritin, besides being a hallmark of  
hereditary hemochromatosis (HH), is frequently found 
in chronic hepatitis C, in alcoholic or non-alcoholic 
steatohepatitis (NASH), and in non-alcoholic fatty liver 
disease (NAFLD).
A raised ferritin level, with an increased transferrin 
saturation and liver iron concentration, is a typical 
presentation of  HH, an autosomal recessive disorder 
linked to HFE gene mutations[3], which account for 
most cases of  HH in northern Europe and the USA[4]. 
Epidemiological studies in Mediterranean populations 
have shown that C282Y occurs only sporadically, 
while H63D is found among 13.5% of  the general 
population[5]. In this area, HFE polymorphism seems to 
have a modest diagnostic relevance, since many cases of  
HH do not display the classic pattern of  mutations[5]. It 
Online Submissions: wjg.wjgnet.com                                          World J Gastroenterol  2009 ���� ��� ������: 2��2�2���   
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has been suggested that HFE mutations may be involved 
in cases of  liver disease complicated by iron overload 
and in patients with type 2 diabetes[6].
Patients with chronic hepatitis C virus (HCV) 
infection often have elevated serum iron indices[7], but 
these do not reflect accurately hepatic iron content, nor 
are they able to predict clinically important endpoints, 
such as progression of  fibrosis and responsiveness to 
interferon-based regimens[8-10]. Studies attempting to 
link iron and the course of  chronic hepatitis C have 
been inconclusive[11]. In chronic hepatitis C, steatosis is 
a common histological finding and occurs in 30%-70% 
of  patients[12-13]. The biological mechanism underlying 
steatosis in HCV infection is not definitively understood 
and is considered to be multifactorial with metabolic 
mechanisms, including insulin resistance (IR)[14] 
and iron overload[8,11,15]. In fact, steatosis in patients 
infected by HCV genotype 1 is linked to a raised 
g-glutamyltransferase (GGT) and to IR as a result of  
lipid peroxidation in the liver[14]. The high prevalence 
of  diabetes in subjects chronically infected with HCV 
has been ascribed to an increase in IR mediated by an 
increase in iron deposits[16,17]. 
In NAFLD, recent studies [18-20] have reported 
conflicting data on the role of  iron in causing liver 
damage. George et al[21] and Bonkovsky et al[22] have 
shown that patients with NAFLD and iron overload 
have more severe liver disease, whereas Younossi et al[19] 
and Angulo et al[20] did not observe any relationship 
between iron and clinical or pathological outcomes in 
patients with NAFLD. Mendler et al[23] have reported 
that patients with NAFLD have no more iron overload 
than patients with isolated steatosis, and that the HFE 
genotype does not influence liver damage, although 
unexplained hepatic iron overload is nearly always 
associated with metabolic abnormalities.
We analyzed in a cross-sectional study a cohort of  
non-obese, non-alcoholic patients with compensated 
chronic liver disease characterized by elevated serum 
ferritin levels, of  varying etiology, excluding HH, to 
reassess the link between hyperferritinemia and other 
markers of  the metabolic syndrome, mainly steatosis.
MATERIALS AND METHODS
Patients
We studied all patients consecutively referred to our 
Gastroenterology & Hepatology Unit, a tertiary referral 
center, between January 2001 and January 2004. Patients 
were included in the study if  they had abnormal liver 
function tests and a high serum ferritin level, and if  their 
clinical workup conclusively excluded a final diagnosis of  
HH. HH was excluded by measurement of  transferrin 
saturation following an overnight fast, according to 
American Association for the Study of  Liver Diseases 
practice guidelines[24].
Serum ferritin was considered raised according to the 
WHO criteria if  > 300 ng/mL in men and > 200 ng/mL 
in women. Patients were excluded if  they had a history 
of  alcohol abuse (alcohol consumption > 30 g/d in men 
and > 20 g/d in women), obesity [body mass index (BMI) 
≥ 30], transferrin saturation > 45%, hepatitis B surface 
antigen positivity, autoimmune hepatitis, celiac disease, 
Wilson disease, α-1-antitripsin deficiency, porphyria 
cutanea tarda, or previous antiviral treatment in patients 
with chronic HCV infection. Alcohol intake and drug 
use or abuse was evaluated through the administration 
of  a questionnaire. Concomitant inflammatory diseases 
potentially capable of  causing hyperferritinemia were 
ruled out on the basis of  the absence of  clinical signs or 
abnormal blood test results (erythrocyte sedimentation 
rate, rheumatoid factor, and C reactive protein). 
One hundred and twenty-four consecutive patients 
fitting the above criteria were selected from about 1800 
subjects admitted for evaluation of  abnormal LFTs to 
our unit (2001-2004). Clinical features, biochemical data, 
HCV and HBV status, histological features and iron 
status parameters were registered at baseline. All patients 
were genetically tested for HFE gene mutations. IR 
was determined by the homeostasis model assessment 
(HOMA) method using the following equation: insulin 
resistance (HOMA-IR) = fasting insulin (µU/mL) × 
fasting glucose (mmol/L)/22.5. 
All patients had liver ultrasound (US); liver biopsy 
was performed only when clinically appropriate and 
in patients who did not refuse. Steatosis on US was 
assessed as present or absent; when present, it was 
graded as mild, moderate or severe by two experienced 
ultrasonographers (always the same throughout the study 
period), who were unaware of  the clinical and laboratory 
results. The presence of  steatosis was determined in a 
qualitative manner according to standardized criteria[25].
HFE mutation analysis
HFE gene mutations were evaluated by a reverse 
hybridization assay (Nuclear Laser Diagnostics) that 
assessed 11 HFE gene mutations: V53M, V59M, H63D, 
H63H, SC65C, C282Y, Q127H, E168Q, E168X, W169X, 
Q283P on DNA from peripheral blood mononuclear 
cells. Extracted DNA fragments were amplified by PCR 
and PCR products were hybridized with allele-specific 
oligonucleotide probes, and the hybridized probes were 
read by a colorimetric reaction.
Histological examination
Biopsies were evaluated for grade and stage according to 
Ishak[26] and, on Perl’s Prussian-blue-stained sections, for 
iron content. Stainable iron was scored as: grade 0, no 
detectable iron; grade 1, granules of  iron visible at 400 × 
magnification; grade 2, discrete iron granules visible at 100 
× magnification; grade 3, iron visible at 25 × magnification, 
and grade 4, masses of  iron visible at 10 × magnification.
Statistics analysis
Continuous variables were summarized as mean ± SD 
and categorical variables as frequency and percentage. 
Multiple logistic and linear regression models were 
used to assess the relationship of  steatosis, high ferritin 
www.wjgnet.com
and chronic liver disease. The dependent variable was 
steatosis on US, coded as 0 (absent) or 1 (present). 
As candidate risk factors for steatosis, we selected 
age, sex, BMI, presence of  cirrhosis, baseline alanine 
aminotransferase (ALT)/aspartate aminotransferase 
(AST), platelets, GGT, ferritin, serum iron, transferrin, 
transferrin saturation, glucose, bilirubin, and diabetes. 
Multiple logistic regression analysis was performed to 
identify independent predictors of  steatosis. Multiple 
linear regression analysis was performed to identify 
independent predictors of  ferritin levels as a continuous 
dependent variable. Variables found to be associated with 
the dependent variables on univariate logistic or linear 
regression at P ≤ 0.10 were included in multivariate 
regression models. Regression analyses were performed 
using PROC LOGISTIC and PROC REG subroutines 
(SAS Institute, Inc., Cary, NC, USA)[23].
RESULTS
Features of  the patients included in the study are shown 
in Table 1. The 124 patients (34 women and 90 men) 
had a mean age of  53.3 ± 1.2 years. The mean value of  
ferritin was 799 ± 75 ng/mL and that of  serum iron was 
126 ± 6.3 µg/dL.
HCV infection was detected in 53 patients (42.7%), 35 
of  whom (28.2%) had NAFLD without overt diabetes, 
11 (8.8%) had NAFLD associated with diabetes, and 11 
had NASH at histology. Finally, 14 patients (11.3%) were 
classified as having cryptogenic chronic hepatitis.
Overall, 92 patients (74.2%) had steatosis on US: 46 
moderate and 46 severe. The etiological pattern of  the 
patients with steatosis was as follows: 35 (38%) subjects 
were infected with HCV, 35 (38%) had NAFLD, 11 
(12%) were diabetic with NAFLD, and 11 (12%) had a 
diagnosis of  NASH at histology. 
HCV infection was detected in 53 patients (42.7%). 
All these were infected by HCV genotype 1b; 36 (68%) 
had steatosis, nine were detected by US and 27 by liver 
biopsy. 
At liver biopsy, performed in 54 patients out of  124 
(43.5%), 27 (50%) had chronic hepatitis C and nine 
(16.6%) had micronodular cryptogenic cirrhosis. Seven 
patients (12.9%) had NAFLD (macrovesicular steatosis) 
and 11 (20.3%), NASH (macrovesicular steatosis and 
lobular inflammation). Seventeen patients (31.5%) had 
siderosis: eight, grade 1 and nine, grade 2.
Among the 11 HFE gene mutations analyzed, only 
two (H63D and C282Y) were present in our population, 
while the remaining nine mutations were not found 
in any patient. H63D and C282Y mutations were 
distributed as follows: 53 patients tested (42.7%) carried 
at least one HFE gene mutation. These were distributed 
as follows: 49 (39.5%) patients were H63D heterozygous, 
two (1.6%) were C282Y heterozygous, and two (1.6%) 
were C282Y/H63D, compound heterozygous. None 
were ultimately diagnosed with HH on clinical and 
laboratory criteria. 
Univariate and multivariate analyses were performed 
to identify predictors of  steatosis. By univariate analysis 
age (P = 0.06), ferritin (P = 0.0006), GGT (P = 0.03) 
and anti-HCV positivity (P = 0.02) were associated with 
steatosis (P < 0.10) (Table 2). By multivariate analysis, 
ferritin (OR: 1.002; 95% CI: 1.001-1.004), and GGT (OR: 
1.007; 95% CI: 1.001-1.013) were the only independent 
predictors of  steatosis (Table 3). The baseline ferritin 
Table 1  Demographic, laboratory and histological features of 
124 patients (mean ± SD)
Variable
�e�n �ge ���r� ��.� ± �.2
Age ���r�, n �%�
   ≤ �0   �� �4�.2�
   > �0   �� ���.��
Sex, n �%�
   ��le   90 ��2.��
   Fem�le   �4 �2�.��
B�I �kg/m2�
   < 2�   �4 ��9.6�
   2��29.9   �0 �40.��
ALT�UNL   �.0 ± �.0
AST�UNL   2.0 ± �.0
GGT�UNL   2.0 ± 0.�
Ferritin �ng/mL� �99.� ± ��.6
Serum iron �µg/dL�  �26 ± 6.�
Pl�telet count × �0�/cmm      ��6 ± �4.��
HO�A score   �.4� ± �.�0
Ste�tosis   92 ��4.2�
Etiolog��
   Anti�HCV   �� �42.��
   NAFLD   �� �2�.2�
   NAFLD/di�betes �� ��.��
   NASH �� ��.��
   Cr��ptogenic   �4 ���.��
Histolog�� ��4�
   Chronic hep�titis C 2� ��0�
   Cirrhosis cr��ptogenic     9 ��6.6�
   NAFLD     � ��2.9�
   NASH   �� �20.��
   HFE mut�tions   �� �42.��
      H6�D heteroz��gous   49 ��9.��
      C2�2Y heteroz��gous   2 ��.6�
      C2�2Y/H6�D compound het   2 ��.6�
ULN: Upper limit of norm�l.
Table 2  Univariate analysis of risk factors for absent/present 
liver steatosis in 124 patients with high serum level ferritin
Variable Steatosis P  value
Absent 
(n  = 32)
Present 
(n  = 92)
Age ���r� �0.9 ± �.� �4.2 ± �.�   0.06
Sex �� ��6.2� �2 ���.2�   0.�4
B�I �kg/m2� 24.4 ± �.2 2�.2 ± �.�   0.�0
ALT�UNL 4�.� ± �.� ���.� ± ��.2 0.�
AST�UNL ��.� ± �.�      �9 ± �0.� 0.�
GGT   9�.� ± 20.� ��4.� ± �9.�   0.0�
Anti�HCV positivit��        24 ���� 2� ��0.4�   0.02
Ferritin �ng/mL�   464 ± ���   �060.� ± �9       0.0006
Serum Iron �µg/dL� 96.� ± �.�  ��� ± �.� 0.�
Pl�telet count × �0�/cmm 2��.� ± �6.�  ��6.9 ±  �.26   0.24
HO�A     �.0 ± 2.2�  �.� ± 2.�   0.2�
HFE mut�tions �4 �4�.�� 40 �4�.4�   0.6�
Di�betes �� ��4.��        �� ��2� 0.2
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and GGT levels in patients with or without steatosis are 
shown in Figures 1 and 2.
To identify predictors of  ferritin levels, univariate 
and multivariate l inear regression analyses were 
performed. Univariate analysis showed that male sex, 
anti-HCV positivity, platelet count, AST, ALT, GGT 
level and steatosis were significantly associated with 
ferritin levels. The model for the independent predictors 
of  ferritin levels as a continuous variable by multiple 
linear regression analysis (Table 4) included anti-HCV 
positivity (P = 0.0028), platelet count (P = 0.0161) and 
steatosis (P < 0.0001). Figure 2 outlines baseline ferritin 
levels according to HCV infection status.
DISCUSSION
Hyperferritinemia is frequent in patients with chronic 
liver disease, whatever the etiology of  the underlying 
damage. In this cohort of  124 non-obese, non-alcoholic 
patients with high serum ferritin levels, without HH, 
the cause of  liver disease was chronic HCV infection 
in 42.7%, NAFLD/NASH in 45.9%, and untraceable 
in 11%. Steatosis on US was predicted independently 
by ferritin and GGT levels. High ferritin levels were 
associated with HCV infection and with more advanced 
liver disease, shown by low platelet counts. 
In our study, no patients could be finally diagnosed 
with HH, although at least one of  the characterized 
HFE gene mutations (C282Y and/or H63D, mostly 
the latter) was found in 50% of  our patients in an 
heterozygote state. In fact, none of  these carriers of  
HFE mutations had a transferrin saturation > 45%, liver 
siderosis beyond grade 1, or evidence of  any other organ 
damage attributable to iron overload. It is noteworthy 
that an excess H63D allele frequency observed in our 
patients, as compared to the 12%-19% range observed 
in the normal population in our area[5,28], suggests that 
heterozygosity for this mutated allele may increase the 
appearance of  high ferritin levels, once predisposing 
factors such as IR, steatosis and cirrhosis are operating.
Chronic hepatitis C, with or without cirrhosis, often 
presents with abnormal iron indices[29,30], particularly 
Table 4  Multivariate analysis of risk factors for high serum 
ferritin levels in 124  patients by linear regression model
Variable b SE P
��le 9�.��� ���.��       0.6�2
ALT�UNL      �0.0���4           �.09��4       0.94�
AST�UNL        �.0602�           �.0��4�       0.��9
GGT�UNL       0.924��         0.��46       0.���
Anti�HCV positivit��        �2�.964 �69.40       0.002�
Pl�telet count × �0�/cmm      �0.002�0         0.00�0     0.0�6�
Ste�tosis 9��.�2��   ��0.4��  < 0.000�
Table 3  Predictors of steatosis in 124 patients by logistic regression model
Predictor Univariate analysis Multivariate analysis
OR (95% CI) P  value OR (95% CI) P  value
Age ���r� 0.962 �0.92���.002�   0.060 0.9� �0.94��.�4� 0.2�
Sex 0.4�� �0.�60��.29�� 0.�4 � �
B�I �kg/m2�           �.0�0 �0.96��.�4� 0.2� � �
ALT�UNL 0.99� �0.99���.00�� 0.�2 � �
AST�UNL 0.99� �0.994��.002� 0.�6 � �
GGT�UNL �.00� ��.00���.0���   0.0�0   �.00� ��.00���.0�4�     0.004�
Anti�HCV positivit�� 0.2�4 �0.��0�0.6�2�   0.00� 0.40 �0.20��.�0� 0.0�
Pl�telet count × �0�/cmm �.000 ��.000��.000� 0.24 � �
Ferritin �ng/mL� �.002 ��.00���.004�     0.0006   �.00� ��.002��.004�     0.0009
Serum Iron �µg/dL� 0.999 �0.99���.00�� 0.�4 � �
HFE mut�tions 0.�96 �0.����2.020� 0.6� � �
Di�betes 0.99� �0.9�6��.004� 0.2� � �
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Figure 1  Baseline GGT levels according to steatosis in 124 non-obese, 
non-alcoholic patients without hereditary haemochromatosis (HH).
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Figure 2  Baseline ferritin levels according to steatosis and HCV infection 
status in 124 non-obese, non-alcoholic patients without hereditary 
haemochromatosis (HH).
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with raised levels of  ferritin, which does not necessarily 
represents iron overload. Several mechanisms have been 
hypothesized to explain the altered iron indices and 
possible liver siderosis, including an excess of  oxygen 
free radicals, increased fibrogenesis through activation 
of  stellate cells and impairment of  the host immune 
response[31-34]. Among our 29 patients with chronic liver 
disease caused by HCV genotype 1b, in whom liver 
biopsy was performed, only 17 had siderosis (eight 
mild, nine moderate, none severe). Theoretically, serum 
ferritin could be elevated as an acute phase reaction 
linked to the necroinflammatory process of  chronic 
hepatitis C, but the moderate increase in ALT and the 
degree of  activity typically observed in these patients 
negates this interpretation, even if  in our analysis 
chronic HCV infection was independently linked to 
higher ferritin levels at multivariate analysis. It is however 
difficult to disentangle the role of  HCV from that of  
steatosis, which is commonly associated with raised 
levels of  ferritin[35,36], and is a common finding in HCV 
infection[37], even when caused by HCV genotype 1[14]. 
In our study, HCV-infected patients also showed a 
moderate degree of  steatosis. NAFLD is known to be by 
itself  strongly associated with the metabolic syndrome, 
which may explain the strong relationship between HCV 
infection and diabetes. The association between IR and 
moderate/severe steatosis in chronic hepatitis C is well 
supported[36-38]. In fact, IR could lead to the development 
of  steatosis of  the liver in HCV-infected patients[14], 
which makes them prone to the onset of  diabetes. 
In NAFLD, lipid peroxidation promotes transition 
from steatosis to steatohepatitis, which involves multiple 
cellular adaptations and evokes biomarkers of  the 
oxidative stress that occurs when fatty acid metabolism 
is altered. The induction of  heme-oxygenase 1 is an 
adaptive response against oxidative damage elicited by 
lipid peroxidation, and may be critical in the progression 
of  the disease[39]. The association we found between 
ferritin and moderate/severe steatosis supports the 
concept that serum ferritin is a risk factor for fatty liver. 
Further support for this hypothesis is lent by the data 
of  Zelber-Sagi et al[40] who demonstrated that NAFLD is 
the major determinant of  increased serum ferritin levels 
at a population-based level. Moreover, they have shown 
that the association between serum ferritin and insulin 
is much more evident in the NAFLD group. Although 
recent studies have suggested that serum ferritin is a 
marker of  IR[42-44], we could not provide evidence for 
a direct correlation between IR and elevated levels of  
serum ferritin. Consonant with Zelber-Sagi et al[40], we 
believe that the association found in previous studies 
between ferritin and IR may depend upon undiagnosed 
NAFLD.
Data from the third National Health and Nutrition 
Examination Survey (1988-1994) show a significant 
association between elevated serum ferritin and newly 
diagnosed diabetes mellitus[16]. We found that 17.7% of  
our patients had type 2 diabetes. In our study, however, 
ferritin levels were not significantly associated with IR, 
as evaluated by HOMA score, as well as by the presence 
of  overt diabetes, probably as a result of  the relatively 
small size of  this sample, in which younger patients 
under evaluation for chronic hepatitis C predominated. 
Although a recent study has suggested that diabetes is 
the main factor accounting for the high ferritin level 
detected in chronic HCV infection[45], we could not 
provide evidence for a direct correlation between IR and 
hyperferritinemia.
An important finding of  this work is the association 
we found between raised ferritin and reduction in platelet 
counts, a known marker of  portal hypertension[46]. We 
confirmed the observation by Bugianesi et al[36] who 
demonstrated that serum ferritin, but not iron stores, 
was a significant predictor of  severe fibrosis in patients 
with NAFLD. All these data provide further evidence 
that hyperferritinemia might be another surrogate 
marker of  advanced liver disease of  any etiology.
According to recent reports, GGT is an independent 
predictor of  liver steatosis[14]. Our data indicate that 
patients with elevated GGT levels have the greatest 
likelihood of  having moderate/severe steatosis. The 
administration of  a questionnaire regarding alcohol 
intake and drug use or abuse makes us confident in 
excluding any role of  these potential confounders on 
GGT levels. Lack of  data on smoking, however, could 
affect the accuracy of  the results[47]. The association 
between GGT levels and steatosis is likely the result of  
the association between regional body fat distribution 
and fatty liver, irrespective of  total body fat quantity, 
which is consistent with the assumption that GGT is a 
surrogate marker of  central fat accumulation. Therefore, 
the GGT level may be a simple and reliable marker of  
visceral and hepatic fat and, by inference, of  hepatic 
IR. Thus, patients with elevated serum ferritin and 
GGT levels are at risk of  developing liver steatosis[48]. 
Modelling the indication for US scanning on these 
predictors would maximize its cost effectiveness. 
The main limitation of  the current study, as well as 
of  other cross-sectional studies, is that it is unable to 
distinguish the temporality of  the associations between 
hyperferritinemia, steatosis and chronic hepatitis C. 
Lack of  histological data in a proportion of  subjects, 
particularly on intra-hepatic iron deposition, could also 
affect the interpretation of  our findings. We are aware 
that the use of  a more sensitive imaging technique such 
as magnetic resonance imaging could improve the rate 
of  steatosis detection. In addition, we cannot exclude the 
possibility that denied alcohol abuse may be responsible 
for the observed prevalence of  steatosis. A further 
methodological issue arises in the potential limitation 
of  the generalizability of  our results to new populations 
and settings. Our study included a Mediterranean cohort 
of  non-obese patients without HH, which limits the 
broad application of  the results.
In conclusion, this study shows that in a non-obese 
cohort of  non alcoholic patients, steatosis and chronic 
HCV infection are the main causes of  hyperferritinemia. 
In Southern European populations, the finding of  high 
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ferritin levels, after the exclusion of  diagnosis of  HH, 
represents a risk factor for steatosis and has clinical 
relevance, being associated with low platelet count.
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serum iron indices, but these do not accurately reflect hepatic iron content, nor 
are they able to predict clinically important endpoints, such as progression of 
fibrosis and responsiveness to interferon-based regimens.
Research frontiers
In this study, the authors showed that, in a non-obese cohort of non-
alcoholic patients, steatosis and chronic HCV infection are the main causes 
of hyperferritinemia. In southern European populations, high ferritin levels, 
after exclusion of a diagnosis of hereditary hemchromatosis (HH), represent a 
risk factor for steatosis and have clinical relevance, being associated with low 
platelet count.
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In a non-obese cohort of non-alcoholic patients with chronically abnormal liver 
function tests, without HH, serum ferritin high level is, therefore, a risk factor for 
steatosis.
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Hyperferritinemia can be used as markers of steatosis in non-obese and non-
alcoholic patients.
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The authors study the underlying liver disease in a cohort of individuals selected 
because they had both chronic liver disease as well as elevated serum ferritin 
levels. They found that most individuals had either chronic HCV or fatty liver 
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